San Diego, California -- Biotechnology company Anaphore has secured $13 million in its first round of venture capital investment.
Anaphore is focused on developing treatments for immune-based diseases and was created through the acquisition of Borean Pharma ApS.
Investors in the round included SR One, Merck Serono Ventures and Aravis Ventures. The company did not disclose how the funding proceeds would be used. |